secwatch.observer — SEC 8-K summary
======================================

Issuer:     AETHLON MEDICAL INC (AEMD)
CIK:        0000882291
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001683168-25-008257
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aethlon Medical Q2 fiscal 2025: operating loss narrows to $1.5M, clinical trial advances
--------------------------------------------------------------------------------

- Cash balance $5.8M at Sept 30, 2025; operating expenses down 48% YoY to $1.5M.
- Operating loss narrowed to $1.5M from $2.8M in the prior-year quarter.
- Nasdaq compliance resolved; AEMD remains listed on the Capital Market.
- Recruitment began for Cohort 2 of Australian Hemopurifier oncology trial with pembrolizumab/nivolumab.
- Long COVID research with UCSF continues; manuscript in preparation for peer-reviewed journal.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882291/000168316825008257/0001683168-25-008257-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882291/000168316825008257/aethlon_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-008257

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer